PRETAM HOLDINGS INC. UNDERWRITING AGREEMENTUnderwriting Agreement • December 22nd, 2023 • PreTam Holdings Inc. • Concrete products, except block & brick • New York
Contract Type FiledDecember 22nd, 2023 Company Industry JurisdictionThe undersigned, PreTam Holdings Inc., a corporation incorporated under the laws of Alberta (the “Company”), hereby confirms its agreement (this “Agreement”) to issue and sell to the underwriter or underwriters, as the case may be, named in Schedule I hereto (each, an “Underwriter” and, collectively, the “Underwriters”), for whom Maxim Group LLC (“Maxim”) is acting as representative (in such capacity, the “Representative”), (A) an aggregate of _______ units (the “Units”), each unit consisting of one Class A Common Share, no par value per share of the Company (“Common Stock”) and the shares of Common Stock sold as part of the Units, the “Firm Shares”) together with a warrant to purchase one share of Common Stock (the “Warrant”) at an exercise price of $_____ per share (the warrants sold as part of the Units, the “Firm Warrants”) and (B) at the election of the Representative, (i) up to an additional _________ shares of Common Stock (the “Option Shares” and together with the Firm Shares,
UNDERWRITING AGREEMENTUnderwriting Agreement • September 5th, 2023 • Edible Garden AG Inc • Agricultural production-crops • New York
Contract Type FiledSeptember 5th, 2023 Company Industry Jurisdiction
MARIZYME, INC. UNDERWRITING AGREEMENTUnderwriting Agreement • February 9th, 2023 • Marizyme Inc • Pharmaceutical preparations • New York
Contract Type FiledFebruary 9th, 2023 Company Industry Jurisdiction
MARIZYME, INC. UNDERWRITING AGREEMENTUnderwriting Agreement • November 2nd, 2022 • Marizyme Inc • Pharmaceutical preparations • New York
Contract Type FiledNovember 2nd, 2022 Company Industry Jurisdiction
AINOS, INC. UNDERWRITING AGREEMENTUnderwriting Agreement • August 12th, 2022 • Ainos, Inc. • Pharmaceutical preparations • New York
Contract Type FiledAugust 12th, 2022 Company Industry JurisdictionThe undersigned, Ainos, Inc., a Texas corporation (the “Company”), hereby confirms its agreement (this “Agreement”) to issue and sell to the underwriter or underwriters, as the case may be, named in Schedule I hereto (each, an “Underwriter” and, collectively, the “Underwriters;”), for whom Maxim Group LLC is acting as representative (in such capacity, the “Representative”) an aggregate of 780,000 units (the “Firm Units” or “Units”) of the Company’s securities, and, at the election of the Representative, up to an additional 117,000 Option Shares (as defined herein and collectively with the shares of Common Stock underlying the Firm Units, the “Shares”), and/or up to an additional 117,000 Option Warrants (as defined herein and collectively with warrants underlying the Firm Units, the “Warrants”). Each Unit consists of one share of the Company’s common stock, par value $0.01 per share (the “Common Stock”) and one Warrant. Each Warrant entitles the holder to purchase one share of Common St
AINOS, INC. UNDERWRITING AGREEMENTUnderwriting Agreement • August 2nd, 2022 • Ainos, Inc. • Pharmaceutical preparations • New York
Contract Type FiledAugust 2nd, 2022 Company Industry JurisdictionThe undersigned, Ainos, Inc., a Texas corporation (the “Company”), hereby confirms its agreement (this “Agreement”) to issue and sell to the underwriter or underwriters, as the case may be, named in Schedule I hereto (each, an “Underwriter” and, collectively, the “Underwriters;”), for whom Maxim Group LLC is acting as representative (in such capacity, the “Representative”) an aggregate of [____] units (the “Firm Units” or “Units”) of the Company’s securities, and, at the election of the Representative, up to an additional [_________] Option Shares (as defined herein and collectively with the shares of Common Stock underlying the Firm Units, the “Shares”), and/or up to an additional [_____] Option Warrants (as defined herein and collectively with warrants underlying the Firm Units, the “Warrants”). Each Unit consists of one share of the Company’s common stock, par value $0.01 per share (the “Common Stock”) and one Warrant. Each Warrant entitles the holder to purchase one share of Common
EDIBLE GARDEN AG INCORPORATED UNDERWRITING AGREEMENTUnderwriting Agreement • April 6th, 2022 • Edible Garden AG Inc • Agricultural production-crops • New York
Contract Type FiledApril 6th, 2022 Company Industry JurisdictionThe undersigned, Edible Garden AG Incorporated, a Delaware corporation (the “Company”), hereby confirms its agreement (this “Agreement”) to issue and sell to the underwriter or underwriters, as the case may be, named in Schedule I hereto (each, an “Underwriter” and, collectively, the “Underwriters;”), for whom Maxim Group LLC is acting as representative (in such capacity, the “Representative”), an aggregate of [____] units (the “Firm Units” or “Units”) of the Company’s securities, and, at the election of the Representative, up to an additional [_________] Option Shares (as defined herein and collectively with the shares of Common Stock underlying the Firm Units, the “Shares”), and/or up to an additional [_____] Option Warrants (as defined herein and collectively with warrants underlying the Firm Units, the “Warrants”). Each Unit consists of one share of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) and one Warrant. Each Warrant entitles the holder to purc
IVEDA SOLUTIONS, INC. UNDERWRITING AGREEMENTUnderwriting Agreement • March 28th, 2022 • Iveda Solutions, Inc. • Services-prepackaged software • New York
Contract Type FiledMarch 28th, 2022 Company Industry JurisdictionThe undersigned, Iveda Solutions, Inc., a Nevada corporation (the “Company”), hereby confirms its agreement (this “Agreement”) to issue and sell to the underwriter or underwriters, as the case may be, named in Schedule I hereto (each, an “Underwriter” and, collectively, the “Underwriters;”), for whom Maxim Group LLC is acting as representative (in such capacity, the “Representative”), an aggregate of [____] shares (the “Firm Shares”) of the Company’s common stock, par value $0.00001 per share (“Common Stock”) and an aggregate of [___] warrants (the “Firm Warrants”), and, at the election of the Representative, up to an additional [_________] shares of Common Stock (the “Option Shares” and collectively with the Firm Shares, the “Shares”), and/or up to an additional [_____] warrants, (the “Option Warrants” and collectively with the Firm Warrants, the “Warrants”). Each Warrant entitles the holder to purchase one share of Common Stock (as more fully described in Section 2 hereof). The Firm
IVEDA SOLUTIONS, INC. UNDERWRITING AGREEMENTUnderwriting Agreement • March 15th, 2022 • Iveda Solutions, Inc. • Services-prepackaged software • New York
Contract Type FiledMarch 15th, 2022 Company Industry JurisdictionThe undersigned, Iveda Solutions, Inc., a Nevada corporation (the “Company”), hereby confirms its agreement (this “Agreement”) to issue and sell to the underwriter or underwriters, as the case may be, named in Schedule I hereto (each, an “Underwriter” and, collectively, the “Underwriters;”), for whom Maxim Group LLC is acting as representative (in such capacity, the “Representative”), an aggregate of [____] shares (the “Firm Shares”) of the Company’s common stock, par value $0.00001 per share (“Common Stock”) and an aggregate of [___] warrants (the “Firm Warrants”), and, at the election of the Representative, up to an additional [_________] shares of Common Stock (the “Option Shares” and collectively with the Firm Shares, the “Shares”), and/or up to an additional [_____] warrants, (the “Option Warrants” and collectively with the Firm Warrants, the “Warrants”). Each Warrant entitles the holder to purchase one share of Common Stock (as more fully described in Section 2 hereof). The Firm
CORPHOUSING GROUP, INC. UNDERWRITING AGREEMENTUnderwriting Agreement • January 31st, 2022 • Corphousing Group Inc. • Real estate • New York
Contract Type FiledJanuary 31st, 2022 Company Industry JurisdictionThe undersigned, Corphousing Group, Inc., a Delaware corporation (the “Company”), hereby confirms its agreement (this “Agreement”) to issue and sell to the underwriter or underwriters, as the case may be, named in Schedule I hereto (each, an “Underwriter” and, collectively, the “Underwriters;”), for whom Maxim Group LLC is acting as representative (in such capacity, the “Representative”), an aggregate of [____] units (the “Firm Units” or “Units”) of the Company’s securities, and, at the election of the Representative, up to an additional [_________] Option Shares (as defined herein and collectively with the shares of Common Stock underlying the Firm Units, the “Shares”), and/or up to an additional [_____] Option Warrants (as defined herein and collectively with warrants underlying the Firm Units, the “Warrants”). Each Unit consists of one share of the Company’s common stock, par value $0.00001 per share (the “Common Stock”) and one Warrant. Each Warrant entitles the holder to purchase
SOCIETY PASS INCORPORATED UNDERWRITING AGREEMENTUnderwriting Agreement • November 12th, 2021 • Society Pass Incorporated. • Services-business services, nec • New York
Contract Type FiledNovember 12th, 2021 Company Industry Jurisdiction
BONE BIOLOGICS CORPORATION UNDERWRITING AGREEMENT 1,510,455 Units Consisting of 1,510,455 Shares of Common Stock And 1,510,455 Warrants to Purchase 1,510,455 Shares of Common StockUnderwriting Agreement • October 15th, 2021 • Bone Biologics Corp • Orthopedic, prosthetic & surgical appliances & supplies • New York
Contract Type FiledOctober 15th, 2021 Company Industry JurisdictionBONE BIOLOGICS CORPORATION, a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the underwriters named in Schedule I hereto (the “Underwriters,” or each, an “Underwriter”), for whom WallachBeth Capital, LLC is acting as Representative (the “Representative”), an aggregate of 1,510,455 Units (the “Firm Units”), each Firm Unit consisting of one share of the Company’s common stock, $0.001 par value per share (the “Common Stock”) and one warrant to purchase one share of Common Stock (the “Warrants” and each a “Warrant”). The 1,510,455 shares of Common Stock referred to in this Section are hereinafter referred to as the “Firm Shares” and the Warrants referred to in this Section are hereinafter referred to as the “Firm Warrants,” and together with the Firm Units and the Firm Shares, the “Firm Securities.” The Firm Warrants shall be issued pursuant to, and shall have the rights and privileges set forth in, a warrant agent ag
BONE BIOLOGICS CORPORATION UNDERWRITING AGREEMENT [____]Units Consisting of [____]Shares of Common Stock And [____] Warrants to Purchase [ ] Shares of Common StockUnderwriting Agreement • October 6th, 2021 • Bone Biologics Corp • Orthopedic, prosthetic & surgical appliances & supplies • New York
Contract Type FiledOctober 6th, 2021 Company Industry JurisdictionBONE BIOLOGICS CORPORATION, a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the underwriters named in Schedule I hereto (the “Underwriters,” or each, an “Underwriter”), for whom WallachBeth Capital, LLC is acting as Representative (the “Representative”), an aggregate of [____]Units (the “Firm Units”), each Firm Unit consisting of one share of the Company’s common stock, $0.001 par value per share (the “Common Stock”) and one warrant to purchase one share of Common Stock (the “Warrants” and each a “Warrant”). The [____] shares of Common Stock referred to in this Section are hereinafter referred to as the “Firm Shares” and the Warrants referred to in this Section are hereinafter referred to as the “Firm Warrants,” and together with the Firm Units and the Firm Shares, the “Firm Securities.” The Firm Warrants shall be issued pursuant to, and shall have the rights and privileges set forth in, a warrant agent agreement
NUTRIBAND, INC. UNDERWRITING AGREEMENT [*] Units Consisting of [*] Shares of Common Stock And [*] Warrants to Purchase [*] Shares of Common StockUnderwriting Agreement • October 1st, 2021 • NutriBand Inc. • Orthopedic, prosthetic & surgical appliances & supplies • New York
Contract Type FiledOctober 1st, 2021 Company Industry JurisdictionNUTRIBAND, INC., a Nevada corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the underwriters named in Schedule I hereto (the “Underwriters,” or each, an “Underwriter”), for whom WallachBeth Capital, LLC is acting as representative (the “Representative”), an aggregate of [__] Units (the “Firm Units”), each Firm Unit consisting of one share of the Company’s common stock, $0.001 par value per share (the “Common Stock”) and one warrant to purchase one share of Common Stock (the “Warrants” and each a “Warrant”). The [__] shares of Common Stock referred to in this Section are hereinafter referred to as the “Firm Shares” and the Warrants referred to in this Section are hereinafter referred to as the “Firm Warrants,” and together with the Firm Units and the Firm Shares, the “Firm Securities.” The Firm Warrants shall be issued pursuant to, and shall have the rights and privileges set forth in, a warrant agent agreement, dated on or be
LIXTE BIOTECHNOLOGY HOLDINGS, INC. UNDERWRITING AGREEMENT [*] Units Consisting of [*] Shares of Common Stock And [*] Warrants to Purchase [*] Shares of Common StockUnderwriting Agreement • November 16th, 2020 • Lixte Biotechnology Holdings, Inc. • Pharmaceutical preparations • New York
Contract Type FiledNovember 16th, 2020 Company Industry JurisdictionLIXTE BIOTECHNOLOGY HOLDINGS, INC., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the underwriters named in Schedule I hereto (the “Underwriters,” or each, an “Underwriter”), for whom WestPark Capital Inc. is acting as representative (the “Representative”), an aggregate of [__] Units (the “Firm Units”), each Firm Unit consisting of one share of the Company’s common stock, $0.001 par value per share (the “Common Stock”) and one warrant to purchase one share of Common Stock (the “Warrants” and each a “Warrant”). The [__] shares of Common Stock referred to in this Section are hereinafter referred to as the “Firm Shares” and the Warrants referred to in this Section are hereinafter referred to as the “Firm Warrants,” and together with the Firm Units and the Firm Shares, the “Firm Securities.” The Firm Warrants shall be issued pursuant to, and shall have the rights and privileges set forth in, a warrant agent agreeme
UNDERWRITING AGREEMENT between XENETIC BIOSCIENCES, INC. and Ladenburg Thalmann & Co. Inc. XENETIC BIOSCIENCES, INC.Underwriting Agreement • October 11th, 2016 • Xenetic Biosciences, Inc. • Pharmaceutical preparations • New York
Contract Type FiledOctober 11th, 2016 Company Industry JurisdictionThe undersigned, Xenetic Biosciences, Inc., a corporation formed under the laws of the State of Nevada (collectively with its subsidiaries and affiliates, including, without limitation, all entities disclosed or described in the Registration Statement (as hereinafter defined) as being subsidiaries or affiliates of Xenetic Biosciences, Inc., the “Company”), hereby confirms its agreement (this “Agreement”) with Ladenburg Thalmann & Co. Inc. (hereinafter referred to as “you” (including its correlatives) or the “Underwriter”) as follows:
OPGEN, INC. UNDERWRITING AGREEMENTUnderwriting Agreement • April 30th, 2015 • Opgen Inc • Services-medical laboratories • New York
Contract Type FiledApril 30th, 2015 Company Industry JurisdictionThe undersigned, OpGen, Inc., a Delaware corporation (the “Company”), hereby confirms its agreement (this “Agreement”) with the several underwriters (such underwriters, for whom Maxim Group LLC is acting as representative (in such capacity, the “Representative”), the “Underwriters” and each an “Underwriter”) to issue and sell to the Underwriters an aggregate of up to 3,277,500 units (“Units”) of the Company’s securities. Each Unit consists of one share of common stock, par value $0.01 per share, of the Company (“Common Stock”), and one warrant to purchase one share of Common Stock at an exercise price equal to $[·] per share (each a “Warrant” and collectively, the “Warrants”). The offering and sale of securities contemplated by this Agreement is referred to herein as the “Offering.”